NR0B2 and allergic disease: Our future aim will be to demonstrate that the ASTA through the positive regulation of SHP-1 could represent a new therapeutic approach in relation to common inflammatory diseases, even for those affected with allergies cannot benefit from the use of Non-steroidal anti-inflammatory drugs (NSAIDs).